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２Abstract
Although activating mutations of B-Raf are the most common genetic abnormalities in human
melanomas1, the mechanism by which mutant B-Raf transforms melanocytes is poorly
understood.  Here we show that the retinoblastoma tumor suppressor protein (pRB) is a
direct target of B-Raf and is inactivated by phosphorylation in melanomas carrying B-Raf
mutations.  In contrast, pRB is undetectable in melanomas with wild-type B-Raf.  Mutant
B-Raf directly interacts with pRB and induces its phosphorylation at serine-249 and
threonine-252 (S249/T252).  Inhibition of B-Raf activity results in dephosphorylation of
pRB at S249/T252 along with other sites in melanoma cells.  S249/T252 are phosphorylated
earlier than other sites during cell cycle entry of normal melanocytes.  Blocking B-Raf
activation precluded S249/T252 phosphorylation in mitogen-stimulated melanocytes, which
was accompanied by the impaired phosphorylation of pRB at other sites.  B-Raf enhanced
CDK2-mediated pRB phosphorylation in an in vitro kinase assay.  These results suggest that
B-Raf is an initiating RB kinase, which triggers inactivation of pRB at the earliest step in the
cell cycle entry of normal melanocytes, and its activating mutations cause deregulated growth,
leading to the development of melanoma.          
Text
As malignant melanoma is an extremely aggressive neoplasm with high mortality,
considerable effort has been made to understand the molecular basis of the disease2, 3.
Genetic abnormalities found in melanoma include activating mutations of B-Raf (30-70% of
cases), point mutations of N-Ras (10-20%), loss-of-function mutations of p53 and PTEN (10-
25%), and mutational activation of CDK4 (less than 5%)4.  Furthermore, it has been reported
that melanoma cells frequently carry loss of chromosomes 9p, 10, and 13, which results in the
deletion of Ink4a, PTEN, and pRB, respectively, and gain of chromosomes 11q and 12q,
which causes amplification of Cyclin D1 and CDK4, respectively5, 6.
Recent analyses employing a genome-wide surveillance of DNA copy numbers and
mutations have revealed the mutually-exclusive pattern of genetic alterations in melanomas
and its relationship to the history of ultraviolet (UV) light exposure7.  B-Raf mutations are
most frequently observed in melanomas arising on the skin with intermittent exposure to UV
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３light such as those on the trunk, arms, and legs, which rarely show the amplification of Cyclin
D1 and CDK4.  In contrast, B-Raf has wild-type configuration in the vast majority of
melanomas from sun-damaged skin, typically on the face, and those with minimal or no UV
exposure (acral and mucosal melanomas).  Instead, these melanomas often harbor multiple
chromosome abnormalities including loss of chromosome 13, deletion of the Ink4a locus, and
CDK4/Cyclin D1 amplification, all of which result in physical or functional inactivation of
pRB8.
The absence of genetic abnormalities directly causing pRB inactivation suggests another
mechanism of inactivation in melanomas carrying B-Raf mutation, because the RB-E2F
pathway plays a crucial role in melanocyte differentiation9 and is altered in almost all
melanoma cells10, especially those of acral and mucosal origin11.  To address this issue, we
first investigated the relationship between B-Raf mutation and pRB expression using 10
melanoma cell lines and 11 samples from primary lesions of patients with malignant
melanoma.  As shown in Fig. 1A, pRB expression was absent or under the detection limit of
immunoblotting in 5 out of 10 melanoma cell lines, whereas normal human epidermal
melanocytes (NHEM) readily expressed RB protein.  In 5 cell lines with intact pRB
expression, RB protein was heavily phosphorylated at multiple sites including S249/T252 and
serine-780 (Ser780).  We concomitantly examined the presence of B-Raf mutations, and
found that T1796A substitution of the BRAF gene, which results in a V599E amino acid
change, was detected in 6 of the 10 cell lines, whereas there were no mutations in other
portions of exon 15, nor anywhere in exon 11 (data not shown).  Interestingly, the cell lines
harboring B-Raf mutation, except for Malme-3M, expressed intact RB protein, whereas all
the cell lines without B-Raf mutation lacked pRB expression (Fig. 1A).  The correlation
between B-Raf mutation and pRB expression was also observed in primary samples (Fig. 1B
shows representative results and the data from all cases are summarized in Table 1).  These
results indicate that pRB is inactivated in almost all melanoma cells by two mechanisms:
hyperphosphorylation in B-Raf mutation-positive cases and loss of protein expression in B-
Raf mutation-negative cases.  
The coexistence of B-Raf mutation and pRB phosphorylation strongly suggests that
activated B-Raf kinase mediates the phosphorylation of pRB in melanoma cells.  To
substantiate this hypothesis, we treated MM-Ac and MM-RU cells with 5-iodo-3-[(3,5-
dibromo-4-hydroxyphenyl) methylene]-2-indolinone (GW5074), a potent cell-permeable B-
Raf kinase inhibitor12, 13, and examined the changes in the phosphorylation status of pRB.
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４The Raf kinase inhibitor almost completely abrogated pRB phosphorylation at multiple sites
including S249/T252 and Ser780 with similar kinetics and extent to the effect on ERK1/2, a
bona fide target of B-Raf (Fig. 2A shows the data from MM-RU cells).  Cell cycle analysis
revealed that G1 arrest was not yet apparent at 24 hours of treatment, when pRB
phosphorylation was completely abrogated, indicating that this effect was not a simple
consequence of growth arrest (Fig. 2A). As GW5074 targets all members of the Raf
family12, 13, we performed the same experiment using siRNA against B-Raf.  Treatment of
MM-Ac and G-361 cells with BRAF siRNA reduced the amounts of phosphorylated species
of pRB in proportion to the decrease in the abundance of B-Raf protein (Fig. 2B).  It is of
note that c-Raf, which was not affected by siRNA against B-Raf, is not able to substitute B-
Raf for pRB phosphorylation in melanoma cells.
Although these results clearly show that B-Raf is involved in pRB phosphorylation in
melanoma cells, it is uncertain whether this effect is direct.  To clarify this point, we first
examined whether B-Raf physically interacts with pRB in melanoma cells.  Co-
immunoprecipitation assays revealed that B-Raf and pRB formed a complex in MM-Ac cells,
which express mutant B-Raf and intact pRB, whereas the association of the two molecules
was not detectable in MM-LH cells, which express normal B-Raf but lack pRB (Fig. 2C).
Furthermore, we demonstrated the colocalization of B-Raf and pRB using confocal
microscopy (Fig. 2D).  Interestingly, the association was observed both in the nuclei and the
cytoplasm, implying that B-Raf plays a role in the nuclear export of pRB, another possible
mechanism of functional inactivation14, 15.
To corroborate that mutant B-Raf directly phosphorylates pRB, we carried out two types
of in vitro kinase assays.  First, B-Raf was immunoprecipitated from melanoma cells
expressing wild-type B-Raf (MM-LH and RPM-MC) and those expressing mutant B-Raf
(MM-Ac and G-361), and subjected to an in vitro kinase assay using highly-purified full-
length pRB as a substrate.  Mutant B-Raf exhibited strong RB kinase activity, which was
comparable to that of purified CDK2/Cyclin A complex, whereas the normal counterpart
possessed a relatively weak activity (Fig. 3A). Next, we performed the same assay with a
combination of recombinant mutant B-Raf kinase (V599E) and purified RB protein, and
confirmed the strong activity of mutant B-Raf against pRB, whose specificity was
demonstrated by complete inhibition with the Raf inhibitor GW5074 (Fig. 3B, left panel).
Taken together, these results support the view that B-Raf acts as RB kinase in melanoma
cells.
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５Next, we sought to identify the site(s) of phosphorylation by B-Raf within the pRB
sequence.  To this end, we performed nano ESI-MS analysis of B-Raf-phosphorylated pRB
as described in Methods.  The Mascot search of the obtained MS spectra identified 4
possible phosphorylated tryptic peptides of pRB (Fig. 3C, peaks 1~4).  A doubly-charged
peak at 819.94 m/z (peak 4) corresponded to the peptide 241-254 containing two
phosphorylated serine/threonine residues (TAVIPINGpSPRpTPR), whereas the other 3 peaks
were considered non-specific because of weak ionic strength.  In order to confirm the results
of nano ESI-MS analysis, we subjected B-Raf-phosphorylated pRB to immunoblotting with 5
different phosphorylation site-specific antibodies. As shown in Fig. 3B, only the antibody
against ppRB-S249/T252 recognized RB protein phosphorylated by B-Raf in vitro.  No
signals were detected by this antibody in untreated pRB and pRB treated with B-Raf in the
presence of the Raf inhibitor, indicating the specificity of this experiment.  These results
strongly suggest that B-Raf preferentially phosphorylates pRB at S249/T252, for which the
kinases responsible are unidentified.
   Finally, we attempted to clarify the biological significance of B-Raf-mediated
phosphorylation of pRB at S249/T252 and its implication in the development of malignant
melanoma.  For this purpose, we first monitored the order of site-specific phosphorylation of
pRB during cell cycle entry of normal human melanocytes.  Primary human melanocytes
were deprived of growth factors for 24 hours to obtain quiescent cells, and stimulated with
growth factors to induce synchronized cell cycle entry.  Serial analysis of DNA histograms
revealed that quiescent melanocytes started to enter the S phase at 24 hours of stimulation,
and became fully cycling at 48 hours (Fig. 4A). During the cell cycle entry of melanocytes,
pRB was initially phosphorylated at S249/T252 and S807/S811 (4 h), followed by
phosphorylation at Ser780, Ser795, and Ser608 (8 h).  This pattern is consistent with
previous reports in which CDK3/Cyclin C phosphorylates S807/S811 at G0 exit16,
CDK4/Cyclin D phosphorylates Ser780 and Ser795 at mid G117, 18, and CDK2/Cyclin E
phosphorylates Ser608 and Ser612 at late G119, 20. To data, however, little is known about
the biological significance of and kinases responsible for S249/T252 phosphorylation.
Phosphorylation at S249/T252 coincided with the activation of B-Raf, as judged by increased
expression and autophosphorylation (Fig. 4B). Blocking B-Raf activation by the Raf
inhibitor GW5074 precluded S249/T252 phosphorylation of pRB in mitogen-stimulated
melanocytes, which was accompanied by impaired phosphorylation of pRB at other sites
including S780 (Fig. 4C).  These results indicate that B-Raf-mediated pRB phosphorylation
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６at S249/T252 occurs very early during the G0/G1 to S phase transition of normal human
melanocytes, and may positively affect the later step of pRB phosphorylation catalyzed by
CDK/Cyclin complexes.  To test the latter notion, we phosphorylated pRB with B-Raf in the
presence of cold ATP, and then subjected the pre-phosphorylated pRB to in vitro kinase assay
with purified CDK2/Cyclin A complex.  As shown in Fig. 4D, B-Raf markedly augmented
RB kinase activity of CDK2/Cyclin A, suggesting that B-Raf-induced S249/T252
phosphorylation is a prerequisite of further phosphorylation of pRB by CDK/Cyclin
complexes.  Via this mechanism, mutant B-Raf triggers the inactivation of pRB and
subsequent deregulated growth of melanocytes, leading to the development of malignant
melanoma.  Our findings shed new light on the mechanisms of malignant transformation of
human melanocytes by mutant B-Raf, and may provide a clue to the development of a better
treatment strategy for malignant melanoma.
Methods
Cell lines and cell culture
The human melanoma cell lines MM-AN, MM-BP, MM-LH, MM-RU, and RPMI-MC were
kindly provided by Dr. H. Randolph Byers (Harvard Medical School, Boston, USA)21, and
MM-Ac by Dr. Hiroshi Katayama (Katayama Dermatology Clinic, Gunma, Japan).  We
purchased HMV-II, Malme-3M, Colo679, and G-361 from ATCC (Manassas, VA, USA), and
normal human epidermal melanocytes (NHEM) from Kurabo Biomedicals (Osaka, Japan).
NHEM were cultured for 24 hours in Medium154S in the absence of growth factors to induce
G0 arrest, and stimulated with growth factors (basic fibroblast growth factor, hydrocortisone,
insulin, transferrin, phorbol myristate acetate, heparin, and bovine pituitary extracts) to
reenter the cell cycle22. Primary samples were obtained from patients admitted to Jichi
Medical School Hospital at the time of diagnostic surgery.  Human specimens were handled
in accordance with the requirements of the institutional review board.   
Cell cycle analysis
The cell cycle profile was obtained by staining DNA with propidium iodide in preparation for
flow cytometry analysis with the FACScan/CellQuest system (Becton-Dickinson, San Jose,
CA).  The size of the sub-G1, G0/G1, and S+G2/M fractions was calculated as a percentage
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７by analyzing DNA histograms using the ModFitLT 2.0 program (Verity Software, Topsham,
ME).
Detection of B-Raf mutations
DNA was isolated from melanoma cell lines and primary samples according to the standard
methods.  Exons 11 and 15 of B-Raf cDNA were amplified by PCR using the following
primer pairs: exon 11, sense 5’-TCCCTCTCSGGCATAAGGTAA-3’ and antisense 5’-
CGAACAGTGAATATTTCCTTTGAT-3’; exon 15, sense 5’-TCATAATGCTTGCTCTGAT
AGGA-3’ and antisense 5’-GGCCAAAAATTTAATCAGTGGA-3’.  PCR products were
subjected to direct DNA sequencing after purification.
Immunological procedures
We performed Western blotting, immunoprecipitation-immunoblotting assays, and
immunohistochemistry using confocal laser microscopy as previously described23.  The
following antibodies (purchased from Cell Signaling Technology, Beverley, MA unless
otherwise stated) were used: anti-pRB (4H1), anti-phosphorylated pRB (Ser249/Thr252)
(Santa Cruz Biotechnology, Santa Cruz, CA), anti-phosphorylated pRB (Ser807/Ser811),
anti-phosphorylated pRB (Ser780), anti-phosphorylated pRB (Ser795), anti-phosphorylated
pRB (Ser 608), anti-phosphorylated pRB (Ser 612) (Calbiochem, San Diego, CA, USA), anti-
B-Raf (F-7; Santa Cruz Biotechnology; #07-453; Upstate, Lake Placid, NY, USA), anti-
phosphorylated B-Raf (Ser 445), anti-c-Raf, anti-phosphorylated ERK1/2 (Thr202/Tyr204),
anti-ERK1/2, and anti-`-actin (C4; ICN Biomedicals, Aurora, OH).
Identification of phosphorylation sites of pRB by nano ESL-MS analysis
Highly-purified full-length RB protein (QED Bioscience, San Diego, CA, USA) was
phosphorylated by recombinant mutant B-Raf kinase (V599E) (Upstate) in vitro according to
the manufacturer's instructions, and resolved on 8% polyacrylamide gels.  RB protein was
excised from gels after staining with Coomassie Brilliant Blue dye, digested with trypsin, and
subjected to nano ESI-MS analysis on a Q-TOF2 mass spectrometer (Micromass MS
Technologies, Manchester, UK) equipped with a nanoflow source.  Parent ion scanning was
performed over the m/z range of 250-3500 with collision energy of 5 eV.       
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８Two step in vitro kinase assays
Highly-purified full-length RB protein (1 μg) was incubated with 0.1 ng of recombinant
mutant B-Raf kinase (V599E) in an appropriate reaction buffer containing cold ATP
according to the manufacturer's instructions. After 30 minutes, the reaction was terminated
by adding 100 nM 5-iodo-3-[(3, 5-dibromo-4-hydroxyphenyl) methylene]-2-indolinone
(GW5074) (Calbiochem).  The reaction mixture was diluted in CDK2 reaction buffer, and
incubated with 1 U/ml purified recombinant CDK2/Cyclin A complex (New England Biolabs,
Beverly, MA, USA) in the presence of [a32P]ATP for 0, 5, 10, 15, and 20 minutes.
Phosphorylated RB proteins were visualized by autoradiography after being resolved on 8%
polyacrylamide gels.
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Table 1  Expression of pRB and mutation of BRAF in primary melanoma specimens
                   BRAF mutation
  pRB expression ＋ －
＋ 2 0
－ 1 8
*Using the chi-square test, significant correlation was obtained between BRAF mutation and pRB expression
(χ2=6.525, P<0.05).
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Figure Legends
Figure 1  Inactivation of pRB and its relationship to B-Raf mutation in melanoma cells.
(A) Whole cell lysates were prepared from 10 human melanoma cell lines and quiescent
primary human epidermal melanocytes (NHEM), and subjected to immunoblot analysis for
the expression of pRB and phosphorylated pRB at specific sites.  The membrane filters were
reprobed with `-actin antibody to verify the equal loading and integrity of samples.  The
absence or presence of BRAF gene mutation is shown at the top.  (B) Expression of pRB
was examined by immunohistochemistry using anti-pRB monoclonal antibody (4H1) and
chicken antibody to mouse immunoglobulin conjugated with Alexa 488 (Amersham
Biosciences) in 11 primary human melanoma samples.  We simultaneously isolated DNA
from the samples and analyzed mutations of the BRAF gene using PCR-direct sequencing.
A point mutation at nt. 1796 (T to A substitution) was detected in 2 out of 2 cases with pRB
expression (#0682 and #2687), whereas the BRAF gene was in wild-type configuration in 8
out of 9 cases lacking pRB expression (#4190 and #51919, data not shown for other cases).
See Table 1 for summary.
Figure 2  Physical and functional interaction of pRB and B-Raf in melanoma cells.
(A) MM-RU cells were cultured in the presence of 10 μM GW5074 for up to 24 hours.
Phosphorylation status of pRB was examined by immunoblotting using phosphorylation site-
specific antibodies as indicated (right panel). We monitored the inhibition of cellular B-Raf
activity by checking ERK1/2 phosphorylation (p-ERK1/2), and equal loading and integrity of
samples by detecting `-actin expression.  Cell cycle analysis was performed at 0 and 24
hours of culture (left panel).  (B) MM-Ac and G-361 cells were treated with 10 μM siRNA
against BRAF and its scrambled control (Santa Cruz Biotechnology) for 24 hours.
Phosphorylation status of pRB was examined by immunoblotting using phosphorylation site-
specific antibodies as indicated (right panel). We monitored the effect and specificity of
siRNA by checking B-Raf and c-Raf expression, respectively.  (C) Whole cell lysates from
MM-Ac and MM-LH cells were subjected to immunoprecipitation with either preimmune
rabbit immunoglobulin (rabbit IgG) or anti-B-Raf polyclonal antibody (Upstate), followed by
immunoblotting with anti-pRB (4H1) and B-Raf (F-7) monoclonal antibodies.  Coomassie
Brilliant Blue staining of the precipitated immunoglobulin heavy chain (IgH) is shown as a
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loading control.  (D) MM-Ac and MM-LH cells were fixed on glass slides in 4%
paraformaldehyde in preparation for confocal microscopy.  pRB and B-Raf were double-
stained with anti-pRB monoclonal (4H1) and anti-B-Raf polyclonal (Upstate) antibodies,
respectively, and appropriate secondary antibodies.
Figure 3 B-Raf phosphorylates pRB at serine-249 and threonine-252 (S249/T252).
(A) B-Raf was immunoprecipitated from melanoma cells without BRAF mutation (MM-LH
and RPM-MC) and with BRAF mutation (MM-Ac and G-361), and subjected to in vitro
kinase assay against purified full-length RB protein (QED Bioscience Inc., San Diego, CA) in
the presence of [a32P]ATP.  Phosphorylated pRB was resolved on 8% polyacrylamide gels
and detected by autoradiography.  Coomassie Brilliant Blue staining of the precipitated
immunoglobulin heavy chain (IgH) indicates the same efficiency of B-Raf
immunoprecipitation.  Recombinant CDK2/Cyclin A complex (New England Biolabs) was
used as a positive control.  (B) Purified full-length RB protein (250ng/lane) was incubated
with 0.05 ng of recombinant mutant B-Raf (V599E) (Upstate) in the absence or presence of
100 nM GW5074 in assay dilution buffer I (Upstate) containing [a32P]ATP at 30 °C for 30
minutes.  Phosphorylated pRB was resolved on 8% polyacrylamide gels and detected by
either autoradiography (left panel) or phosphorylation site-specific pRB antibodies (right
panel).  To verify the equal loading of samples, we performed Coomassie Brilliant Blue
staining of the gel (left panel) and immunoblot with anti-pRB antibody (right panel).  (C)
ESI-MS spectrum in the range of 400-900 m/z for tryptically-digested B-Raf-phosphorylated
pRB is shown.  The Mascot search of the spectra identified 4 possible phosphorylated tryptic
peptides (peak 1~4).
Figure 4 B-Raf phosphorylates pRB at the initial step of G0/G1 to S phase transition and
facilitates later pRB phosphorylation by CDK/Cyclin complexes in normal human
melanocytes.
(A) Cell cycle analysis was performed at the indicated time points in mitogen-stimulated
NHEM.  (B) Whole cell lysates were prepared at the indicated time points, and subjected to
immunoblot analysis for the site-specific phosphorylation and abundance of pRB and the
expression and phosphorylation (mobility shift) of B-Raf.  (C) Quiescent NHEM were
stimulated with growth factors in the absence (-) or presence (+) of 10 μM GW5074, and pRB
phosphorylation at S249/T252 and Ser780 was examined at the indicated time points.  (D)
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We performed a two-step in vitro kinase assay as described in Methods to investigate the
effects of B-Raf-mediated phosphorylation of pRB on RB kinase activity of CDK2/Cyclin A
complex.
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